X0202 SCHEDULE 13G 0001699737 XXXXXXXX LIVE Common Stock, $0.00001 par value per share 09/02/2026 0001699382 PMV Pharmaceuticals, Inc. 69353Y103 400 Alexander Park Drive, Suite 301 PRINCETON NJ 08540 Rule 13d-1(c) Samsara BioCapital, L.P. b DE 0.00 3788734.00 0.00 3788734.00 3788734.00 5.0 PN Samsara BioCapital GP, LLC b DE 0.00 3788734.00 0.00 3788734.00 3788734.00 5.0 OO Samsara Opportunity Fund, L.P. b DE 0.00 3788733.00 0.00 3788733.00 3788733.00 5.0 PN Samsara Opportunity Fund GP, LLC b DE 0.00 3788733.00 0.00 3788733.00 3788733.00 5.0 OO Srinivas Akkaraju b X1 0.00 7577467.00 0.00 7577467.00 7577467.00 9.9 IN PMV Pharmaceuticals, Inc. 400 Alexander Park Drive, Suite 301, PRINCETON, NJ, 08540. The names of the persons filing this report (collectively, the "Reporting Persons") are: Samsara BioCapital, L.P. ("Samsara LP") Samsara BioCapital GP, LLC ("Samsara GP") Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") Srinivas Akkaraju ("Dr. Akkaraju") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. c/o Samsara BioCapital, LLC 628 Middlefield Road Palo Alto, CA 94301 All of the entities were organized in Delaware; Dr. Akkaraju is a United States citizen. Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Reporting Persons' beneficial ownership of the Issuer's securities includes: (i) 3,620,000 shares of common stock, pre-funded warrants ("Pre-Funded Warrants") exercisable for up to 3,400,000 shares of common stock and common warrants ("Common Warrants" and, together with the Pre-Funded Warrants, the "Warrants") exercisable for up to 7,020,000 shares of common stock directly held by Samsara LP and (ii) 3,620,000 shares of common stock, Pre-Funded Warrants exercisable for up to 3,400,000 shares of common stock and Common Warrants exercisable for up to 7,020,000 shares of common stock directly held by Samsara Opportunity Fund. Each of the Warrants contains a provision (the "Beneficial Ownership Blockers") which precludes exercise of the Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. By virtue of the Beneficial Ownership Blocker, each of Samsara LP and Samsara Opportunity Fund is currently prohibited from exercising the Warrants to the extent that such exercise would result in the Reporting Persons' beneficial ownership of more than 7,577,467 shares of common stock. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP. Samsara Opportunity GP is the sole general partner of Samsara Opportunity Fund and Dr. Akkaraju is the managing member of Samsara Opportunity GP. Each of Samsara Opportunity GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara Opportunity Fund. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon the sum of (i) 53,458,058 shares of common stock outstanding as of August 14, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 14, 2026 and (ii) 22,055,000 shares of common stock issued in the Issuer's public offering of equity securities that closed on September 2, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on September 2, 2026, and giving effect to Warrants, to the extent exercisable within 60 days hereof, as referenced herein. Dr. Akkaraju beneficially owns 9.99% of the Issuer's outstanding common stock. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of Dr. Akkaraju's cover page has been rounded down to 9.9%. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 99.1 Joint Filing Agreement Samsara BioCapital, L.P. /s/ Srinivas Akkaraju 09/15/2026 Samsara BioCapital GP, LLC /s/ Srinivas Akkaraju 09/15/2026 Samsara Opportunity Fund, L.P. /s/ Srinivas Akkaraju 09/15/2026 Samsara Opportunity Fund GP, LLC /s/ Srinivas Akkaraju 09/15/2026 Srinivas Akkaraju /s/ Srinivas Akkaraju 09/15/2026